达沙替尼诱发急性淋巴细胞白血病患者低血糖症。
Dasatinib-induced hypoglycemia in a patient with acute lymphoblastic leukemia.
作者信息
Lundholm Michelle D, Charnogursky Gerald A
机构信息
Department of Internal Medicine Loyola University Medical Center Maywood IL USA.
Department of Medicine Division of Endocrinology Loyola University Health Care System Maywood IL USA.
出版信息
Clin Case Rep. 2020 Apr 27;8(7):1238-1240. doi: 10.1002/ccr3.2901. eCollection 2020 Jul.
Abstract
Tyrosine kinase inhibitors can cause significant hypoglycemia in patients with diabetes on other antihyperglycemic medications. These patients should be monitored, and their medications adjusted accordingly.
摘要
酪氨酸激酶抑制剂可使正在服用其他降糖药物的糖尿病患者发生严重低血糖。应对这些患者进行监测，并相应调整其用药。
相似文献
1
Dasatinib-induced hypoglycemia in a patient with acute lymphoblastic leukemia.达沙替尼诱发急性淋巴细胞白血病患者低血糖症。
Clin Case Rep. 2020 Apr 27;8(7):1238-1240. doi: 10.1002/ccr3.2901. eCollection 2020 Jul.
2
Dasatinib: a tyrosine kinase inhibitor for the treatment of chronic myelogenous leukemia and philadelphia chromosome-positive acute lymphoblastic leukemia.达沙替尼：一种用于治疗慢性粒细胞白血病和费城染色体阳性急性淋巴细胞白血病的酪氨酸激酶抑制剂。
Clin Ther. 2007 Nov;29(11):2289-308. doi: 10.1016/j.clinthera.2007.11.005.
3
Dasatinib-induced complete molecular response after allogeneic hematopoietic stem cell transplantation in Philadelphia chromosome-positive acute lymphoblastic leukemia resistant to prior imatinib-containing regimen: a case report and discussion.达沙替尼诱导费城染色体阳性急性淋巴细胞白血病对既往含伊马替尼方案耐药患者异基因造血干细胞移植后完全分子缓解：1 例病例报告并讨论
Med Oncol. 2010 Dec;27(4):1123-6. doi: 10.1007/s12032-009-9347-0. Epub 2009 Nov 3.
4
Spontaneous subdural hematoma in a patient with Philadelphia chromosome-positive acute lymphoblastic leukemia with normal platelet count after dasatinib treatment.达沙替尼治疗后血小板计数正常的费城染色体阳性急性淋巴细胞白血病患者发生自发性硬膜下血肿。
Platelets. 2015;26(5):491-4. doi: 10.3109/09537104.2014.935316. Epub 2014 Jul 15.
5
Combination therapy of BCR-ABL-positive B cell acute lymphoblastic leukemia by tyrosine kinase inhibitor dasatinib and c-JUN N-terminal kinase inhibition.酪氨酸激酶抑制剂达沙替尼联合 c-JUN N-末端激酶抑制治疗 BCR-ABL 阳性 B 细胞急性淋巴细胞白血病。
J Hematol Oncol. 2020 Jun 18;13(1):80. doi: 10.1186/s13045-020-00912-3.
6
Interstitial pneumonitis associated with dasatinib treatment for chronic myeloid leukemia or acute lymphoblastic leukemia: case series and a literature review.达沙替尼治疗慢性髓性白血病或急性淋巴细胞白血病相关的间质性肺炎：病例系列及文献复习。
Ther Adv Respir Dis. 2022 Jan-Dec;16:17534666221135322. doi: 10.1177/17534666221135322.
7
Therapeutic targeting of LCK tyrosine kinase and mTOR signaling in T-cell acute lymphoblastic leukemia.靶向 T 细胞急性淋巴细胞白血病中的 LCK 酪氨酸激酶和 mTOR 信号通路的治疗策略。
Blood. 2022 Oct 27;140(17):1891-1906. doi: 10.1182/blood.2021015106.
8
Effect of the tyrosine kinase inhibitors on the growth in children with Philadelphia chromosome-positive acute lymphoblastic leukemia: a case-control study.酪氨酸激酶抑制剂对费城染色体阳性儿童急性淋巴细胞白血病生长的影响：一项病例对照研究。
Lancet Reg Health West Pac. 2023 Jun 10;38:100818. doi: 10.1016/j.lanwpc.2023.100818. eCollection 2023 Sep.
9
Medication adherence among adults prescribed imatinib, dasatinib, or nilotinib for the treatment of chronic myeloid leukemia.接受伊马替尼、达沙替尼或尼洛替尼治疗慢性髓性白血病的成年人的药物依从性。
J Oncol Pharm Pract. 2015 Feb;21(1):19-25. doi: 10.1177/1078155213520261. Epub 2014 Feb 6.
10
Effect of the tyrosine kinase inhibitors (sunitinib, sorafenib, dasatinib, and imatinib) on blood glucose levels in diabetic and nondiabetic patients in general clinical practice.酪氨酸激酶抑制剂（舒尼替尼、索拉非尼、达沙替尼和伊马替尼）对一般临床实践中糖尿病和非糖尿病患者血糖水平的影响。
J Oncol Pharm Pract. 2011 Sep;17(3):197-202. doi: 10.1177/1078155210378913. Epub 2010 Aug 4.
引用本文的文献
1
Diazoxide-Responsive Hypoglycemia in a Child Receiving Dasatinib for Treatment of B-Cell Acute Lymphoblastic Leukemia.一名接受达沙替尼治疗B细胞急性淋巴细胞白血病的儿童出现对二氮嗪有反应的低血糖症。
JCEM Case Rep. 2024 Dec 4;2(12):luae219. doi: 10.1210/jcemcr/luae219. eCollection 2024 Dec.
2
Senolytic therapy in mild Alzheimer's disease: a phase 1 feasibility trial.轻度阿尔茨海默病的衰老细胞清除疗法：1 期可行性试验。
Nat Med. 2023 Oct;29(10):2481-2488. doi: 10.1038/s41591-023-02543-w. Epub 2023 Sep 7.
3
Senolytic therapy to modulate the progression of Alzheimer's Disease (SToMP-AD) - Outcomes from the first clinical trial of senolytic therapy for Alzheimer's disease.调节阿尔茨海默病进展的衰老细胞溶解疗法（SToMP-AD）——阿尔茨海默病衰老细胞溶解疗法首次临床试验的结果
Res Sq. 2023 Apr 24:rs.3.rs-2809973. doi: 10.21203/rs.3.rs-2809973/v1.
4
G protein-coupled receptor inhibition of beta-cell electrical excitability and insulin secretion depends on Na/K ATPase activation.G 蛋白偶联受体抑制β细胞电兴奋性和胰岛素分泌依赖于 Na/K ATP 酶的激活。
Nat Commun. 2022 Oct 29;13(1):6461. doi: 10.1038/s41467-022-34166-z.
本文引用的文献
1
Adverse effects of dasatinib on glucose-lipid metabolism in patients with chronic myeloid leukaemia in the chronic phase.达沙替尼对慢性期慢性髓性白血病患者糖脂代谢的不良影响。
Sci Rep. 2019 Nov 26;9(1):17601. doi: 10.1038/s41598-019-54033-0.
2
Dasatinib improves insulin sensitivity and affects lipid metabolism in a patient with chronic myeloid leukaemia.达沙替尼可改善一名慢性髓性白血病患者的胰岛素敏感性并影响脂质代谢。
BMJ Case Rep. 2016 Feb 12;2016:bcr2015214284. doi: 10.1136/bcr-2015-214284.
3
Tyrosine Kinase Inhibitors and Diabetes: A Novel Treatment Paradigm?酪氨酸激酶抑制剂与糖尿病：一种新的治疗模式？
Trends Endocrinol Metab. 2015 Nov;26(11):643-656. doi: 10.1016/j.tem.2015.09.003. Epub 2015 Oct 19.
4
Tyrosine kinase inhibitors: their on-target toxicities as potential indicators of efficacy.酪氨酸激酶抑制剂：其针对目标的毒性作为疗效的潜在指标。
Drug Saf. 2013 Jun;36(6):413-26. doi: 10.1007/s40264-013-0050-x.
5
Rapid amelioration of hyperglycemia facilitated by dasatinib in a chronic myeloid leukemia patient with type 2 diabetes mellitus.达沙替尼促进一名慢性髓性白血病合并2型糖尿病患者高血糖的快速改善。
Intern Med. 2012;51(19):2763-6. doi: 10.2169/internalmedicine.51.8314. Epub 2012 Oct 1.
6
Loss of PDGF-B activity increases hepatic vascular permeability and enhances insulin sensitivity.PDGF-B 活性丧失会增加肝血管通透性，并增强胰岛素敏感性。
Am J Physiol Endocrinol Metab. 2011 Sep;301(3):E517-26. doi: 10.1152/ajpendo.00241.2011. Epub 2011 Jun 14.
7
Effect of the tyrosine kinase inhibitors (sunitinib, sorafenib, dasatinib, and imatinib) on blood glucose levels in diabetic and nondiabetic patients in general clinical practice.酪氨酸激酶抑制剂（舒尼替尼、索拉非尼、达沙替尼和伊马替尼）对一般临床实践中糖尿病和非糖尿病患者血糖水平的影响。
J Oncol Pharm Pract. 2011 Sep;17(3):197-202. doi: 10.1177/1078155210378913. Epub 2010 Aug 4.
8
Dasatinib: a potent SRC inhibitor in clinical development for the treatment of solid tumors.达沙替尼：一种在研的 SRC 抑制剂，用于治疗实体瘤。
Cancer Treat Rev. 2010 Oct;36(6):492-500. doi: 10.1016/j.ctrv.2010.02.015. Epub 2010 Mar 11.
9
Cytoplasmic signalling by the c-Abl tyrosine kinase in normal and cancer cells.正常细胞和癌细胞中c-Abl酪氨酸激酶的细胞质信号传导
Biol Cell. 2008 Nov;100(11):617-31. doi: 10.1042/BC20080020.
10
Fasting glucose improvement under dasatinib treatment in an accelerated phase chronic myeloid leukemia patient unresponsive to imatinib and nilotinib.达沙替尼治疗对伊马替尼和尼罗替尼无反应的加速期慢性髓性白血病患者时的空腹血糖改善情况
Leuk Res. 2008 Oct;32(10):1626-8. doi: 10.1016/j.leukres.2008.01.015. Epub 2008 Mar 5.
Zotero 插件